European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling